Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
 
  
   
Insider Information:   Gergen Mark J
Relationship:  
City:   San Diego
State:   CA
   
Insider Summary:
  
   
Companies Owned :   3    
Direct Shares   657,039    

Indirect Shares

   0      
Direct Value   $2,134,971    

Indirect Value

   $0      
Total Shares   657,039      
Total Value   $2,134,971      


Mirati Therapeutics, Inc. $337,408 Poseida Therapeutics, Inc. $1,797,563 Mirati Therapeutics, Inc. $337,408 Poseida Therapeutics, Inc. $1,797,563
 


Historical Performance :
Based on 6 Month Return Percentages
Buys 
Sells 

     Total Filings :
    0   
    0    

     Stock price went up :
    0   
    0    
     Stock price went down :
    0   
    0    
   
     Gain/Loss Ratio :
   0.0   
   0.0   
     Percentage Gain/Loss :
     0.0%
   0.0%
     
   
Holdings :
     Menu Company Name Ticker Relation Direct Date Direct Shares Indirect Date Indirect Shares Total Value Sold  
            Amylin Pharmaceuticals Inc AMLN SVP, Corporate Develop... 2012-08-08 0 2012-08-08 0    Premium*  
            Mirati Therapeutics, Inc. MRTX Executive VP, COO 2016-01-15 5,748 2016-01-15 0    Premium*  
            Poseida Therapeutics, Inc. PSTX 2024-03-01 651,291 2022-02-01 0    Premium*  
* Premium Members only  

Records found :    59         Free Registration Required For Full Results.    Limit: 25

 Download
  Page 2 of 3
Ticker Company Name Relation   Off-Dir-10% Trans. Date Form Action Price Mkt Value D/I Shares    Holdings   
Rank

  
3m +/-  
Form
AMLN Amylin Pharmaceuticals In... Sr VP, Corporate Development   •       –      –    2007-09-04 4 AS $49.00 $49,500 D/D (1,000) 2,937 0 -
AMLN Amylin Pharmaceuticals In... Sr VP, Corporate Development   •       –      –    2007-10-01 4 OE $16.80 $8,400 D/D 500 3,437 0 -
AMLN Amylin Pharmaceuticals In... Sr VP, Corporate Development   •       –      –    2007-10-01 4 AS $49.83 $24,915 D/D (500) 2,937 0 -
AMLN Amylin Pharmaceuticals In... Sr VP, Corporate Development   •       –      –    2007-10-03 4 AS $50.00 $25,000 D/D (500) 2,937 0 -
AMLN Amylin Pharmaceuticals In... Sr VP, Corporate Development   •       –      –    2007-10-03 4 OE $16.80 $8,400 D/D 500 3,437 0 -
AMLN Amylin Pharmaceuticals In... Sr VP, Corporate Development   •       –      –    2007-11-01 4 OE $16.80 $8,400 D/D 500 3,437 0 -
AMLN Amylin Pharmaceuticals In... Sr VP, Corporate Development   •       –      –    2007-11-01 4 AS $44.00 $22,000 D/D (500) 2,937 0 -
AMLN Amylin Pharmaceuticals In... Sr VP, Corporate Development   •       –      –    2008-02-01 4 A $37.00 $6,734 D/D 182 3,069 0 -
AMLN Amylin Pharmaceuticals In... Sr VP Corporate Development   •       –      –    2009-02-03 4 A $11.80 $6,903 D/D 585 4,506 0 -
AMLN Amylin Pharmaceuticals In... Sr VP Corporate Development   •       –      –    2009-03-04 4 A $0.00 $0 I/I 2,550 3,455 0 -
AMLN Amylin Pharmaceuticals In... SVP Corporate Development   •       –      –    2010-02-03 4 A $0.00 $0 I/I 1,360 4,815 0 -
AMLN Amylin Pharmaceuticals In... SVP Corporate Development   •       –      –    2010-02-03 4 A $17.83 $7,346 D/D 412 6,079 0 -
AMLN Amylin Pharmaceuticals In... SVP, Corporate Development   •       –      –    2011-03-01 4 A $0.00 $0 D/D 15,000 21,666 0 -
AMLN Amylin Pharmaceuticals In... SVP, Corporate Development   •       –      –    2011-03-01 4 A $0.00 $0 I/I 1,630 6,445 0 -
AMLN Amylin Pharmaceuticals In... SVP, Corporate Development   •       –      –    2012-01-10 4 A $0.00 $0 D/D 15,000 37,477 0 -
AMLN Amylin Pharmaceuticals In... SVP, Corporate Development   •       –      –    2012-02-08 4 D $16.47 $51,601 D/D (3,133) 42,344 0 -
AMLN Amylin Pharmaceuticals In... SVP, Corporate Development   •       –      –    2012-02-08 4 A $0.00 $0 D/D 8,000 45,477 0 -
AMLN Amylin Pharmaceuticals In... SVP, Corporate DevelopmentSVP,   •       –      –    2012-03-01 4 S $17.11 $31,585 D/D (1,846) 53,814 0 -
AMLN Amylin Pharmaceuticals In... SVP, Corporate DevelopmentSVP,   •       –      –    2012-03-06 4 A $0.00 $0 I/I 1,529 7,974 0 -
AMLN Amylin Pharmaceuticals In... SVP, Corporate DevelopmentSVP,   •       –      –    2012-03-06 4 A $0.00 $0 D/D 10,000 63,814 0 -
AMLN Amylin Pharmaceuticals In... SVP, Corporate DevelopmentSVP,   •       –      –    2012-07-25 4 A $14.62 $13,684 D/D 936 64,750 0 -
AMLN Amylin Pharmaceuticals In... SVP, Corporate DevelopmentSVP,   •       –      –    2012-08-08 4 D $31.00 $328,085 I/I (10,583) 0 0 -
AMLN Amylin Pharmaceuticals In... SVP, Corporate DevelopmentSVP,   •       –      –    2012-08-08 4 D $31.00 $1,648,611 D/D (53,181) 0 0 -
AMLN Amylin Pharmaceuticals In... SVP, Corporate DevelopmentSVP,   •       –      –    2012-08-08 4 A $31.00 $1,648,611 D/D 53,181 53,181 0 -
AMLN Amylin Pharmaceuticals In... SVP, Corporate DevelopmentSVP,   •       –      –    2012-08-08 4 D $31.00 $2,007,256 D/D (64,750) 0 0 -
  59  Records found
  1   2  3      
  Page 2 of 3  
 
Free Registration Required For Full Results.    Limit: 25

 
 
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
OE - Options Exercised A - Aquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us